Russell C. Langan, MD, FACS, FSSO
Dr. Russell Langan is a surgical oncologist at RWJBarnabas Health and the Rutgers Cancer Institute of New Jersey. His practice primarily focuses on the management of tumors of the pancreas and intestinal cancers. He is skilled in complex surgical techniques, including the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of malignant peritoneal mesothelioma.[1]
Dr. Langan collaborates with a multidisciplinary team of experts in treating patients with cancer to ensure that his patients have the best possible outcomes. He strives to provide the highest level of expertise and precision toward improving survival rates through the use of novel peri-operative multi-disciplinary treatment strategies.
Education and Career
Dr. Langan earned his undergraduate degree at Cornell University and his medical degree from St. George’s University. He completed his internship and residency in General Surgery at Georgetown University Hospital and followed that with fellowships in tumor immunotherapy and surgical oncology within the Surgery Branch at the National Cancer Institute, National Institutes of Health. He completed another fellowship in Complex Surgical Oncology at Memorial Sloan Kettering Cancer Center, where he received specialized training in the surgical management of intestinal cancers.[1]
In addition to his surgical practice, Dr. Langan holds the titles of Chief of Surgical Oncology and Hepatopancreatobiliary Surgery at the Cooperman Barnabas Medical Center and Associate Chief Surgical Officer of System Integration and Quality and Director of Surgical Oncology of the Northern Region of RWJ Barnabas Health and Rutgers Cancer Institute. He has received numerous awards, including from the National Institutes of Health, Health and Human Services, Georgetown University Hospital, the District of Columbia Chapter of the American College of Surgeons, and the Society of Black Academic Surgeons.
Research
Dr. Langan has authored more than 30 peer-reviewed articles and seven book chapters dedicated to surgical oncology and has been invited to lecture and present at national professional meetings. His article on “Expression of PD-L1 in Patients With Malignant Peritoneal Mesothelioma: A Pilot Study” which appeared in the September 2022 issue of the Journal of Surgical Research is frequently cited by other mesothelioma researchers.[2] He has been an associate investigator on numerous clinical trials.
Professional Memberships
Dr. Langan is a member of the American College of Surgeons, the Society of Surgical Oncology, the American Hepatopancreatobiliary Association, the Association for Academic Surgery, and the Society for Surgery of the Alimentary Tract.
